Cancer/testis antigens expression and autologous serological response in a set of Brazilian non-Hodgkin's lymphoma patients

Cancer Immunology, Immunotherapy

Volumn 61, Issue 12, 2012, Pages 2207-2214

  Inaoka, Riguel J ^a   Jungbluth, Achim A ^b   Gnjatic, Sacha ^b   Ritter, Erika ^b   Hanson, Nicole C ^b   Frosina, Denise ^b   Tassello, Jodie ^b   Etto, Leina Y ^a   Bortoluzzo, Adriana B ^c   Alves, Antonio C ^a   Colleoni, Gisele W B ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c INSPER INSTITUTE OF EDUCATION AND RESEARCH   (Brazil)

Author keywords

Cancer testis antigens; Humoral response; Non Hodgkin's lymphoma

Indexed keywords

CANCER TESTIS ANTIGEN; GAGE ANTIGEN; MELANOMA ANTIGEN; MELANOMA ANTIGEN C1; MELANOMA ANTIGEN C2; NY ESO 1 ANTIGEN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ANTIBODY TITER; ANTIGEN DETECTION; ANTIGEN EXPRESSION; BLOOD SAMPLING; BRAZIL; CANCER CLASSIFICATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER TISSUE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNOHISTOCHEMISTRY; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN FAMILY; RETROSPECTIVE STUDY; REVIEW; TISSUE MICROARRAY; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; BRAZIL; FEMALE; HUMANS; IMMUNITY, HUMORAL; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; LYMPHOMA, B-CELL; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84870976831     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-012-1285-6     Document Type: Review

References (51)

1. Caballero OL, Chen YT (2009) Cancer/testis (CT) antigens: Potential targets for immunotherapy. Cancer Sci 100(11):2014-2021
2. Almeida LG, Sakabe NJ, de Oliveira AR et al (2009) CTdatabase: A knowledge-base of high-throughput and curated data on cancer-testis antigens. Nucleic Acids Res 37:D816-D819
3. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ (2005) Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 5:615-625
4. Tureci O, Sahin U, Zwick C et al (1998) Identification of a meiosis-specific protein as a member of the class of cancer/testis antigens. Proc Natl Acad Sci U S A 95:5211-5216
5. Ono T, Kurashige T, Harada N et al (2001) Identification of proacrosin binding protein sp32 precursor as a human cancer/ testis antigen. Proc Natl Acad Sci U S A 98:3282-3287
6. Romanienko PJ, Camerini-Otero RD (1999) Cloning, characterization, and localization of mouse and human SPO11. Genomics 61:156-169
7. Loukinov DI, Pugacheva E, Vatolin S et al (2002) BORIS, a novel male germ-line-specific protein associated with epigenetic reprogramming events, shares the same 11-zinc-finger domain with CTCF, the insulator protein involved in reading imprinting marks in the soma. Proc Natl Acad Sci U S A 99:6806-6811
8. Atanackovic D, Hildebrandt Y, Jadczak A et al (2010) Cancertestis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells. Haematologica 95(5):785-793
9. Zhu X, Asa SL, Ezzat S (2008) Fibroblast growth factor 2 and estrogen control the balance of histone 3 modifications targeting MAGE-A3 in pituitary neoplasia. Clin Cancer Res 14:1984-1996
10. Yang B, O'Herrin SM, Wu J et al (2007) MAGE-A, MAGE-B, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell lines. Cancer Res 67:9954-9962
11. Peikert T, Specks U, Farver C et al (2006) Melanoma antigen A4 is expressed in non-small cell lung cancers and promotes apoptosis. Cancer Res 66:4693-4700
12. Monte M, Simonatto M, Peche LY et al (2006) MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents. Proc Natl Acad Sci U S A 103:11160-11165
13. Bai S, He B, Wilson EM (2005) Melanoma antigen gene protein MAGE-11 regulates androgen receptor function by modulating the interdomain interaction. Mol Cell Biol 25:1238-1257
14. Nagao T, Higashitsuji H, Nonoguchi K et al (2003) MAGE-A4 interacts with the liver oncoprotein gankyrin and suppresses its tumorigenic activity. J Biol Chem 278:10668-10674
15. Cilensek ZM, Yehiely F, Kular RK et al (2002) A member of the GAGE family of tumor antigens is an anti-apoptotic gene that confers resistance to Fas/CD95/APO-1, interferon-gamma, taxol and gamma-irradiation. Cancer Biol Ther 1:380-387
16. Oi S, Natsume A, Ito M et al (2009) Synergistic induction of NY-ESO-1 antigen expression by a novel histone deacetylase inhibitor, valproic acid, with 5-aza-20-deoxycytidine in glioma cells. J Neurooncol 92:15-22
17. Sigalotti L, Fratta E, Coral S et al (2004) Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-20-deoxycytidine. Cancer Res 64:9167-9171
18. De Smet C, Lurquin C, Lethe B et al (1999) DNA methylation is the primary silencing mechanism for a set of germ line-and tumor-specific genes with a CpG-rich promoter. Mol Cell Biol 19:7327-7335
19. Andrade VC, Vettore AL, Felix RS et al (2008) Prognostic impact of cancer/testis antigen expression in advanced stage multiple myeloma patients. Cancer Immun 8:2
20. Jungbluth AA, Ely S, DiLiberto M et al (2005) The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation. Blood 106:167-174
21. Chen YT, Chadburn A, Lee P et al (2010) Expression of cancer testis antigen CT45 in classical Hodgkin lymphoma and other B-cell lymphomas. Proc Natl Acad Sci U S A 107(7):3093-3098
22. Heidebrecht HJ, Claviez A, Kruse ML et al (2006) Characterization and expression of CT45 in Hodgkin's lymphoma. Clin Cancer Res 12:4804-4811
23. Velazquez EF, Jungbluth AA, Yancovitz M et al (2007) Expression of the cancer/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM)-correlation with prognostic factors. Cancer Immun 7:11
24. Goydos JS, Patel M, Shih W (2001) NY-ESO-1 and CTp11 expression may correlate with stage of progression in melanoma. J Surg Res 98:76-80
25. Suyama T, Shiraishi T, Zeng Y et al (2010) Expression of cancer/ testis antigens in prostate cancer is associated with disease progression. Prostate 70(16):1778-1787
26. Riener MO, Wild PJ, Soll C et al (2009) Frequent expression of the novel cancer testis antigen MAGE-C2/CT-10 in hepatocellular carcinoma. Int J Cancer 124:352-357
27. Atanackovic D, Luetkens T, Hildebrandt Y et al (2009) Longitudinal analysis and prognostic effect of cancer-testis antigen expression in multiple myeloma. Clin Cancer Res 15:1343-1352
28. Perez D, Herrmann T, Jungbluth AA et al (2008) Cancer testis antigen expression in gastrointestinal stromal tumors: New markers for early recurrence. Int J Cancer 123(7):1551-1555
29. Bellati F, Napoletano C, Tarquini E et al (2007) Cancer testis antigen expression in primary and recurrent vulvar cancer: Association with prognostic factors. Eur J Cancer 43(17):2621-2627
30. Kim J, Reber HA, Hines OJ et al (2006) The clinical significance of MAGEA3 expression in pancreatic cancer. Int J Cancer 118:2269-2275
31. Yakirevich E, Sabo E, Lavie O et al (2003) Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens in serous ovarian neoplasms. Clin Cancer Res 9:6453-6460
32. Duan Z, Duan Y, Lamendola DE et al (2003) Overexpression of MAGE/GAGE genes in paclitaxel/doxorubicin-resistant human cancer cell lines. Clin Cancer Res 9:2778-2785
33. Xie X, Wacker HH, Huang S et al (2003) Differential expression of cancer testis genes in histological subtypes of non-Hodgkin's lymphomas. Clin Cancer Res 9(1):167-173
34. Ait-Tahar K, Liggins AP, Collins GP et al (2009) Cytolytic T-cell response to the PASD1 cancer testis antigen in patients with diffuse large B-cell lymphoma. Br J Haematol 146(4):396-407
35. Cooper CD, Liggins AP, Ait-Tahar K et al (2006) PASD1, a DLBCL-associated cancer testis antigen and candidate for lymphoma immunotherapy. Leukemia 20(12):2172-2174
36. Liggins AP, Brown PJ, Asker K et al (2004) A novel diffuse large B-cell lymphoma-associated cancer testis antigen encoding a PAS domain protein. Br J Cancer 91(1):141-149
37. NCCN (2007) National Comprehensive Cancer Network. The complete library of practice guidelines in oncology (online). Version 2007. Available from. URL:http://www.nccn.org
38. Jaffe E, Harris NL, Stein H et al (2008) World health organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon
39. Kononen J, Bubendorf L, Kallioniemi A et al (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4:844-847
40. Hedvat CV, Hegde A, Chaganti RS et al (2002) Application of tissue microarray technology to the study of non-Hodgkin's and Hodgkin's lymphoma. Hum Pathol 33:968-974
41. Chen YT, Stockert E, Chen Y et al (1994) Identification of the MAGE-1 gene product by monoclonal and polyclonal antibodies. Proc Natl Acad Sci U S A 91(3):1004-1008
42. Jungbluth AA, Stockert E, Chen YT et al (2000) Monoclonal antibody MA454 reveals a heterogeneous expression pattern of MAGE-1 antigen in formalin-fixed paraffin embedded lung tumours. Br J Cancer 83(4):493-497
43. Dhodapkar MV, Osman K, Teruya-Feldstein J et al (2003) Expression of cancer/testis (CT) antigens MAGE-A1, MAGEA3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease. Cancer Immun 23(3):9
44. Nelson PT, Zhang PJ, Spagnoli GC et al (2007) Cancer/testis (CT) antigens are expressed in fetal ovary. Cancer Immun 12(7):1
45. Sharma P, Shen Y, Wen S et al (2006) Cancer-testis antigens: Expression and correlation with survival in human urothelial carcinoma. Clin Cancer Res 12(18):5442-5447
46. Oba-Shinjo SM, Caballero OL, Jungbluth AA et al (2008) Cancer-testis (CT) antigen expression in medulloblastoma. Cancer Immun 8:7
47. Zhuang R, Zhu Y, Fang L et al (2006) Generation of monoclonal antibodies to cancer/testis (CT) antigen CT10/MAGE-C2. Cancer Immun 6:7
48. Vaughan HA, Svobodova S, Macgregor D et al (2004) Immunohistochemical and molecular analysis of human melanomas for expression of the human cancer-testis antigens NY-ESO-1 and LAGE-1. Clin Cancer Res 10(24):8396-8404
49. Gnjatic S, Old LJ, Chen YT (2009) Autoantibodies against cancer antigens. Methods Mol Biol 520:11-19
50. Geldmacher A, Freier A, Losch FO et al (2011) Therapeutic vaccination for cancer immunotherapy: Antigen selection and clinical responses. Hum Vaccin 7:115-119
51. Palucka K, Ueno H, Fay J et al (2011) Dendritic cells and immunity against cancer. Int J Med 269(1):64-73